Immunome (IMNM) to Release Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM) is projected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Immunome to post earnings of ($0.72) per share and revenue of $3.16 million for the quarter.

Immunome (NASDAQ:IMNM) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Trading Down 0.4 %

IMNM opened at $8.15 on Tuesday. The company has a market cap of $650.18 million, a P/E ratio of -1.00 and a beta of 1.93. The company’s 50 day moving average is $9.72 and its 200-day moving average is $11.49. Immunome has a 1-year low of $8.12 and a 1-year high of $26.70.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on IMNM. Guggenheim decreased their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Stephens restated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Finally, Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has an average rating of “Buy” and an average target price of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.